These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2900230)

  • 1. Auditory evoked potentials as possible predictors of outcome in schizophrenic outpatients.
    Hegerl U; Gaebel W; Gutzman H; Ulrich G
    Int J Psychophysiol; 1988 Aug; 6(3):207-14. PubMed ID: 2900230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Auditory evoked potentials in schizophrenic patients before and during neuroleptic treatment. Relationship to psychopathological state.
    Adler G; Gattaz WF
    Eur Arch Psychiatry Clin Neurosci; 1993; 242(6):357-61. PubMed ID: 8323986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Schizophrenia, psychoticism, neuroleptics, and auditory evoked potentials.
    Schlör KH; Moises HW; Haas S; Rieger H
    Pharmacopsychiatry; 1985 Sep; 18(5):293-6. PubMed ID: 4048264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Auditory event-related potentials, auditory digit span, and clinical symptoms in chronic schizophrenic men on neuroleptic medication.
    Stefánsson SB; Jónsdóttir TJ
    Biol Psychiatry; 1996 Jul; 40(1):19-27. PubMed ID: 8780851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Latency increase of auditory-evoked potential component N1 predicts poor neuroleptic response in schizophrenic patients.
    Adler G; Markert U; Gattaz WF
    Pharmacopsychiatry; 1994 Mar; 27(2):68-9. PubMed ID: 7913236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Residual symptoms and P300 in schizophrenic outpatients.
    Juckel G; Müller-Schubert A; Gaebel W; Hegerl U
    Psychiatry Res; 1996 Nov; 65(1):23-32. PubMed ID: 8953658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ERPs in schizophrenia: effects of antipsychotic medication.
    Ford JM; White PM; Csernansky JG; Faustman WO; Roth WT; Pfefferbaum A
    Biol Psychiatry; 1994 Aug; 36(3):153-70. PubMed ID: 7948453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N2 and P3 components of event-related potential in first-episode schizophrenic patients: scalp topography, medication, and latency effects.
    Demiralp T; Uçok A; Devrim M; Isoglu-Alkaç U; Tecer A; Polich J
    Psychiatry Res; 2002 Aug; 111(2-3):167-79. PubMed ID: 12374634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serotonergic dysfunction in schizophrenia assessed by the loudness dependence measure of primary auditory cortex evoked activity.
    Juckel G; Gallinat J; Riedel M; Sokullu S; Schulz C; Möller HJ; Müller N; Hegerl U
    Schizophr Res; 2003 Nov; 64(2-3):115-24. PubMed ID: 14613676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Duration of a clozapine trial in neuroleptic-resistant schizophrenia.
    Meltzer HY
    Arch Gen Psychiatry; 1989 Jul; 46(7):672. PubMed ID: 2567591
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of medication history on midlatency auditory evoked responses in schizophrenia.
    Erwin RJ; Shtasel D; Gur RE
    Schizophr Res; 1994 Feb; 11(3):251-8. PubMed ID: 7910754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P300 alterations in schizophrenic patients experiencing auditory hallucinations.
    Papageorgiou C; Oulis P; Vasios C; Kontopantelis E; Uzunoglu N; Rabavilas A; Christodoulou GN
    Eur Neuropsychopharmacol; 2004 May; 14(3):227-36. PubMed ID: 15056482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Long latency auditory evoked potentials in schoolchildren and adolescents with epilepsy].
    Zgorzalewicz M
    Przegl Lek; 2006; 63 Suppl 1():8-13. PubMed ID: 17471817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Schizophrenics with small P300: a subgroup with a neurodevelopmental disturbance and a high risk for tardive dyskinesia?
    Hegerl U; Juckel G; Müller-Schubert A; Pietzcker A; Gaebel W
    Acta Psychiatr Scand; 1995 Feb; 91(2):120-5. PubMed ID: 7778469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interpeak latency of auditory event-related potentials (P300) in senile depression and dementia of the Alzheimer type.
    Sumi N; Nan'no H; Fujimoto O; Ohta Y; Takeda M
    Psychiatry Clin Neurosci; 2000 Dec; 54(6):679-84. PubMed ID: 11145468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of clozapine on auditory event-related potentials in schizophrenia.
    Umbricht D; Javitt D; Novak G; Bates J; Pollack S; Lieberman J; Kane J
    Biol Psychiatry; 1998 Oct; 44(8):716-25. PubMed ID: 9798075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is clozapine response different in neuroleptic nonresponders vs partial responders?
    Osser DN; Albert LG
    Arch Gen Psychiatry; 1990 Feb; 47(2):189-90. PubMed ID: 1967927
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of risperidone on auditory information processing in neuroleptic-naive patients with schizophrenia spectrum disorders.
    Korostenskaja M; Dapsys K; Siurkute A; Maciulis V; Ruksenas O; Kähkönen S
    Acta Neurobiol Exp (Wars); 2006; 66(2):139-44. PubMed ID: 16886724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in auditory P3 event-related potential in schizophrenia and depression.
    Blackwood DH; Whalley LJ; Christie JE; Blackburn IM; St Clair DM; McInnes A
    Br J Psychiatry; 1987 Feb; 150():154-60. PubMed ID: 2888501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The P 300 potential in schizophrenia].
    Laurent A; Garcia-Larrea L; Dalery J; Terra JL; D'Amato T; Marie-Cardine M; Mauguière F
    Encephale; 1993; 19(3):221-7. PubMed ID: 8275907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.